Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases.
Biologic modifiers
Cytotoxic T-lymphocyte antigen 4
Hemophagocytic lymphohistiocytosis
Lipopolysaccharide-responsive beige-like anchor
Precision therapy
Signal transducer and activator of transcription 1 gain of function
Signal transducer and activator of transcription 3 gain of function
Journal
Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
16
6
2021
Statut:
ppublish
Résumé
Precision therapy is a concept in which medical treatment is tailored to the patient's individual needs based on individual characteristics and mechanism of disease. Primary immunodysregulatory disorders are an expanding group of primary immunodeficiency diseases that are characterized by early onset autoimmunity and autoinflammation. Precision therapy allows for the alteration of the aberrant immune response leading to clinical improvement of disease related manifestations. This article reviews targeted precision-based therapy for treatment of cytotoxic T-lymphocyte antigen haploinsufficiency, lipopolysaccharide-responsive beige-like anchor deficiency, activated PI3K deficiency syndrome, signal transducer and activator of transcription- 1 and -3 - gain-of-function disorders, and disorders of inflammasome activation.
Identifiants
pubmed: 32654696
pii: S0889-8561(20)30021-7
doi: 10.1016/j.iac.2020.04.001
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-526Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.